Anti-KRT13 for IHC / Keratin 13, clone MSVA-613M

Antibody in 1X PBS with 0.05% BSA, 0.05% sodium azide. Cytokeratin 13 (KRT13) is a type I intermediate filament protein expressed predominantly in the suprabasal layers of stratified squamous epithelium, where it contributes to structural integrity and epithelial differentiation. Cytokeratin 13 Antibody for IHC is widely used to detect KRT13 expression in formalin-fixed, paraffin-embedded tissues, supporting analysis of squamous epithelial organization and differentiation. Cytokeratin 13 antibody, also known as KRT13 antibody or CK13 antibody, is a well-established marker of non-keratinizing squamous epithelium and suprabasal cell layers.KRT13 is characteristically co-expressed with keratin 4 in stratified epithelia such as the esophagus, oral mucosa, cervix, and other non-keratinizing squamous tissues. Its expression is largely restricted to suprabasal epithelial cells and is absent in basal proliferative layers, providing a clear distinction between differentiated and progenitor cell compartments. This layer-specific distribution makes Cytokeratin 13 a valuable marker for assessing epithelial maturation, tissue stratification, and cellular organization within squamous epithelia.This Cytokeratin 13 Antibody for IHC incorporates clone MSVA-613M, a monoclonal antibody extensively evaluated using tissue microarray (TMA) analysis across a broad panel of normal and cancer tissues. TMA data demonstrate consistent cytoplasmic staining in suprabasal squamous epithelial cells with minimal background in non-squamous tissues, supporting high specificity for KRT13-expressing cell populations. This large-scale tissue validation enables reliable comparison of expression patterns across diverse tissue types within a standardized experimental framework.In immunohistochemistry, Cytokeratin 13 antibody staining appears as strong cytoplasmic HRP-DAB brown signal in suprabasal epithelial layers, with clear sparing of basal cells and most non-epithelial tissues. TMA-based cancer panels further demonstrate that KRT13 expression is retained in many squamous cell carcinomas, where staining highlights differentiated tumor cell populations, while non-squamous tumors such as adenocarcinomas and mesenchymal tissues typically remain negative. This differential expression pattern provides valuable contrast for identifying squamous lineage and assessing tumor differentiation status.The detection of KRT13 is particularly informative in studies of epithelial differentiation and disease progression, as alterations in its expression pattern have been associated with dysplasia, loss of differentiation, and carcinoma development in squamous tissues. Changes in suprabasal staining intensity or distribution can therefore provide insight into epithelial remodeling and pathological transformation.Overall, Cytokeratin 13 antibody reagents provide reliable and specific detection of KRT13 in suprabasal squamous epithelium, supporting immunohistochemical analysis of epithelial differentiation, tissue architecture, and disease-associated alterations in stratified epithelial tissues, with strong validation across TMA datasets.This antibody is part of a broader Cytokeratin 13 antibody collection supporting epithelial differentiation and squamous tissue analysis.This antibody is also part of a broader collection of IHC antibodies validated by tissue microarray analysis, supporting consistent staining across normal and cancer tissues.